Two Sigma Advisers’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-505,900
| Closed | -$804K | – | 2752 |
|
|
2024
Q1 | $804K | Sell |
505,900
-81,000
| -14% | -$120K | ﹤0.01% | 1674 |
|
|
2023
Q4 | $504K | Buy |
586,900
+112,900
| +24% | +$99.1K | ﹤0.01% | 1921 |
|
|
2023
Q3 | $507K | Buy |
474,000
+106,600
| +29% | +$221K | ﹤0.01% | 1786 |
|
|
2023
Q2 | $952K | Sell |
367,400
-1,400
| -0.4% | -$4.99K | ﹤0.01% | 1557 |
|
|
2023
Q1 | $1.5M | Buy |
368,800
+39,300
| +12% | +$182K | ﹤0.01% | 1426 |
|
|
2022
Q4 | $1.65M | Buy |
329,500
+42,800
| +15% | +$268K | ﹤0.01% | 1333 |
|
|
2022
Q3 | $3.75M | Buy |
286,700
+89,700
| +46% | +$1.36M | 0.01% | 877 |
|
|
2022
Q2 | $2.53M | Buy |
197,000
+2,600
| +1% | +$36K | 0.01% | 1094 |
|
|
2022
Q1 | $2.96M | Sell |
194,400
-72,400
| -27% | -$1.13M | 0.01% | 1047 |
|
|
2021
Q4 | $4.72M | Buy |
266,800
+101,000
| +61% | +$1.94M | 0.01% | 794 |
|
|
2021
Q3 | $3.48M | Buy |
165,800
+131,600
| +385% | +$2.9M | 0.01% | 959 |
|
|
2021
Q2 | $674K | Buy |
34,200
+7,100
| +26% | +$166K | ﹤0.01% | 1811 |
|
|
2021
Q1 | $788K | Buy |
+27,100
| New | +$759K | ﹤0.01% | 1789 |
|
Two Sigma Advisers's NGM Position: Q2 2024 in Review
Two Sigma Advisers sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 505,900 shares — an estimated $804K sold.
Two Sigma Advisers first reported a position in NGM in Q1 2021 and held it in 13 quarters. The position peaked at $4.72M in Q4 2021. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Two Sigma Advisers reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Two Sigma Advisers sold 505,900 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $804K.
- Two Sigma Advisers first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Two Sigma Advisers's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $4.72M in Q4 2021.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.